Search

Objective: To analyze the expression and clinical characteristics of CD68 in bone marrow and peripheral blood of patients with acute myeloid leukemia (AML)., Methods: The expression of CD68 in bone marrow blast cells was detected by four-color flow cytometry in 50 newly diagnosed AML patients and 23 controls. The expression of CD68 in peripheral blood of 85 newly diagnosed AML patients, 29 remission AML patients and 24 controls was detected by ELISA. The correlation between the expression rate of non-M3 AML bone marrow CD68, peripheral blood CD68 concentration and white blood cell count and other clinical data was compared respectively., Results: The median CD68 expression rate in myeloid leukemia cells of non-M3 AML patients was 19.7%, significantly higher than control (0.2%) (P<0.001). The median concentration of non-M3 CD68 in peripheral blood was 67.97 pg/ml, significantly higher than in control (29.94 pg/ml)（P<0.01）. There was no statistically significant difference in the plasma CD68 concentration of the peripheral blood between the newly diagnosed (45.72 pg/ml) and the remission stage (55.12 pg/ml) of non-M3 AML patients by paired analysis (P>0.05). The results showed that the higher the expression rate of CD68 in bone marrow, the higher the count of white blood cells in peripheral blood, and the lower the count of hemoglobin and platelet in peripheral blood. The higher the plasma concentration of CD68 in peripheral blood, the higher the white blood cell count and the lower the complete remission rate., Conclusion: The expression of CD68 both in bone marrow and peripheral blood of patients with non-M3 AML is higher than that of control group. Patients with high expression of CD68 show a low rate of complete remission, suggesting that the expression level of CD68 is correlated with treatment response.

Objective: To analyze the results of immunophenotyping in patients with acute T-lymphoblastic leukemia (T-ALL) so as to improve the understanding of early T-cell precursor acute T-lymphoblastic leukemia (ETP-ALL) and near ETP-ALL with elevated CD5., Methods: The results of immunophenotypes in 62 patients with newly diagnosed adult T-ALL in our hospital were retrospectively analyzed. According to the expression of CD5, CD1a, CD8 and My/S antigens, the patients were divided into 3 groups: ETP, near ETP and non-ETP. The immunophenotypic characteristics and basic clinical data of three groups were compared and analyzed., Results: There were significant differences in age, white blood cell and plt counts as well as percentage of bone marrow blasts among three groups (P＜0.05). ETP and near ETP mainly belonged to Pro T and pre T, and non-ETP mainly belonged to cortical T and mature T. The positive rates of My/S, CD1a, CD8 and CD5 were significantly different among three groups (P＜0.01). The positive rates of CD4 and CD3 in non-ETP group were significantly higher than those in ETP and near-ETP group (P＜0.01). The positive rate of CD56 in near-ETP group was 50%, which was significantly higher than that in ETP group (16.7%) and non-ETP group (0%) (P＜0.01)., Conclusion: According to the expression of CD5, CD1a, CD8 and My/S antigens, T-ALL patients can be divided into three groups: ETP, near ETP and non ETP, the immunophenotypes and basic clinical data among 3 groups are statistically different.